Cdk5, a therapeutic target for Alzheimer's disease?

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):137-42. doi: 10.1016/j.bbapap.2003.11.019.

Abstract

Alzheimer's disease (AD) represents the leading cause for senile dementia affecting more than 4 million people worldwide. AD patients display a triad of pathological features including brain atrophy caused by neuronal loss, beta-amyloid plaque and neurofibrillary tangles. We previously show that Cyclin-dependent kinase 5 (Cdk5) is deregulated in AD brains and may contribute to the pathogenesis of AD. In AD brains, a calpain cleavage product of its physiological regulator p35, p25 is elevated. p25 causes prolonged activation of Cdk5 and alteration of its substrate specificity. The implications of p25/Cdk5 in neurotoxicity, beta-amyloid plaque and neurofibrillary tangle pathology will be discussed.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / enzymology
  • Alzheimer Disease / metabolism*
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Cyclin-Dependent Kinase 5
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism
  • Cyclin-Dependent Kinases / physiology
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Nerve Tissue Proteins / metabolism

Substances

  • Amyloid beta-Protein Precursor
  • Enzyme Inhibitors
  • Nerve Tissue Proteins
  • neuronal Cdk5 activator (p25-p35)
  • Cyclin-Dependent Kinase 5
  • CDK5 protein, human
  • Cyclin-Dependent Kinases